SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,180,209.38070502. The last known price of Ethereum is 2,270.17304981 USD and is up 0.59 over the last 24 hours. It is currently trading on 14230 active market(s) with $5,193,092,001.43 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

A reported major Binance hack has become the dominant catalyst, raising concerns about exchange security and potential selling pressure across crypto, including Ethereum. Traders are split between viewing ETHs decline as a buying opportunity and warning that the breach and broader risk-off sentiment could bring further losses.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 636,822,022.65079832 with 590,150,211.79771733 in circulation. The last known price of Solana is 94.05303263 USD and is down -1.56 over the last 24 hours. It is currently trading on 1189 active market(s) with $1,556,044,818.54 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solanas pullback amid broader crypto weakness dominates discussion, with traders also voicing concern that the reported Binance security incident could undermine confidence across the market. Some view the decline as a buying-and-staking opportunity, while others point to bearish momentum and warn of further downside.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech-led selloff, fueled by weak Big Tech earnings and renewed doubts about the returns on heavy AI spending, has put QQQ in focus. Traders are split between expecting an oversold rebound and warning of further downside, while speculation about Iran talks and oil prices adds to the volatility.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY discussion centers on a volatile rebound after a sharp selloff, with traders linking the move to falling oil and hopes for progress in U.S.-Iran talks, including a possible reopening of the Strait of Hormuz. Some see a relief rally, while others doubt the reports and warn that midterm uncertainty and concerns about AI-related tech valuations could keep markets choppy.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating U.S.-Iran tensions and reported attacks threatening oil flows through the Strait of Hormuz are driving attention to USO and keeping crude prices elevated. Traders are divided between expecting further supply disruption and higher oil prices, and betting that diplomatic progress or a ceasefire could quickly unwind the geopolitical risk premium.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming quarterly report is the dominant focus, with traders debating whether strong AI-driven growth and guidance can meet expectations already viewed as exceptionally high. Bulls anticipate another beat, while skeptics point to the stocks rich valuation and recent AI-sector weakness as risks if guidance disappoints or merely meets the bar.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is drawing attention after a sharp semiconductor selloff, as investors question whether massive AI infrastructure spending will generate adequate returns; weak Intel guidance and broader tech selling added pressure. Traders are split between fears of an AI-trade unwind and expectations of a rebound, citing strong chip demand and oversold conditions.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs ahead of Q3 earnings has drawn attention, with traders citing BRIUMVIs sales growth and bullish call-option activity. Buyout and short-squeeze theories are also prominent, but remain speculation rather than confirmed catalysts.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its upcoming earnings report has traders focused on whether the ad-tech business can sustain growth amid concerns about the broader ad market, competition and analyst downgrades. Bulls argue the decline overlooks strong profitability and growth, while bears fear weaker results or guidance could deepen the downturn.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of a competing treatment for recurrent respiratory papillomatosis has focused attention on the threat to Precigens PAPZIMEOS and contributed to a sharp after-hours selloff. Traders disagree on how much competition it poses: some see Inovios surgery-free regimen as an advantage, while others point to Precigens first-mover position, established sales, and full approval.

statis crypto Watchlist

Bitcoin

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up Next 

Equity

Moderna will report on Friday, while the SITC meeting will bring fresh cancer-treatment findings from Immunocore and Candel.

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 4.68% on an annualized basis producing an average annual return of 13.63%. Currently, Vertex Pharmaceuticals has a marketread more...

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

VRTX is poised for a Q3 earnings beat as strong demand for Trikafta, Alyftrek's growth and rising Casgevy and Journavx sales drive expectations.

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.

BHC Q3 Earnings Preview: Here's What You Should Know 

Bausch Health reports Q3 2026 results on Oct. 28, with $2.75 billion in expected sales. Explore key segment drivers and mixed earnings surprise history.

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change.

Key PointsThe biotech company has grown its annual revenue by more than 600% over the past decade...

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement...

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Vertex will report results on Monday, putting Journavx and Casgevy sales and its $10 billion Crinetics acquisition in focus.</li><li>Pfizer and BioNTech report on Tuesday, with Pfizer’s newer medicines and recent cancer-treatment advances drawing attention.</li><li>Amgen reports Tuesday and Novo Nordisk follows on Wednesday, spotlighting MariTide’s development and Wegovy sales.</li></ul><p>Biotech stocks head into a busy earnings week after beating the broader market, with Pfizer, Novo Nordisk and Moderna set to report earnings alongside a fresh round of cancer-treatment data.&nbsp;</p><p>Healthcare and biotech rallied the previous week, with the&nbsp;<a href="https://stocktwits.com/symbol/IBB">iShares Biotechnology ETF (IBB)</a> gaining 5%, the&nbsp;<a href="https://stocktwits.com/symbol/XBI">SPDR S&amp;P Biotech ETF (XBI)</a> climbing 4%, and the&nbsp;<a href="https://stocktwits.com/symbol/XLV">Health Care Select Sector SPDR Fund (XLV)</a> rising 3%. Comparatively, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> fell 0.6%, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> dropped 2%.</p><p><img src="https://news.stocktwits-cdn.com/koyfin_20261102_072345224_2e2499ab82.png" alt="koyfin_20261102_072345224.png"></p><div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Date</td><td>Ticker/Event</td><td>What To Watch</td></tr><tr><td>Nov.2</td><td>VRTX</td><td>Q3 results</td></tr><tr><td>Nov.3</td><td>PFE / AMGN / BNTX / MDGL</td><td>Q3 results</td></tr><tr><td>Nov.3</td><td>SITC</td><td>Regular abstracts become public&nbsp;</td></tr><tr><td>Nov.4</td><td>NVO</td><td>Q3 results</td></tr><tr><td>Nov.4 - Nov.8</td><td>SITC</td><td>Cancer-immunotherapy meeting in Phoenix</td></tr><tr><td>Nov.5</td><td>IOVA</td><td>Q3 results</td></tr><tr><td>Nov.6</td><td>MRNA</td><td>Q3 results</td></tr><tr><td>Nov.6</td><td>SITC / IMCR / CADL</td><td>Late-breaking abstracts release; Immunocore and Candel presentations</td></tr><tr><td>Nov.7</td><td>IMCR / CADL</td><td>Immunocore oral presentation and Candel glioblastoma findings</td></tr></tbody></table></figure></div><h2 class="st-heading-2"><strong>Vertex Looks Beyond Cystic Fibrosis</strong></h2><p>Vertex Pharmaceuticals will report results on Monday after the close, with investors looking for more growth from medicines outside its core cystic-fibrosis business.</p><p>Its non-opioid pain drug Journavx brought in $49.6 million in second-quarter sales, while gene-editing treatment Casgevy generated $76.4 million. In August, Vertex raised its full-year revenue forecast to $13.1 billion to $13.2 billion, including at least $500 million from the two drugs. That forecast did not include its $10 billion acquisition of Crinetics Pharmaceuticals, completed Sept.1. The deal added Palsonify, a once-daily pill for acromegaly, a disorder caused by excess growth hormone.&nbsp;</p><h2 class="st-heading-2"><strong>Pfizer Puts Its Cancer Business To The Test</strong></h2><p>Pfizer (PFE) will report on Tuesday, after a busy week for its cancer business. The FDA cleared Talzenna plus Xtandi for earlier use in metastatic prostate cancer with certain DNA-repair gene mutations. The next day, Pfizer said Elrexfio helped patients live longer without their multiple myeloma worsening in a Phase 3 trial against standard treatments. Researchers are still collecting data to determine its effect on overall survival.</p><p>For the earnings report, the question is whether newer medicines can keep making up for weaker COVID-related sales. Revenue from Pfizer’s launched and acquired products grew 18%, excluding currency effects, in the second quarter, helping the company raise the midpoint of its annual revenue forecast by $500 million.</p><p>BioNTech, Pfizer’s COVID-vaccine partner, also reports Tuesday.</p><h2 class="st-heading-2"><strong>Amgen And Novo Bring Obesity Back Into View</strong></h2><p>Amgen (AMGN) will report on Tuesday after the close, with an update on its obesity drug MariTide among the items to watch. Its Phase 3 Maritime program is studying weight management as well as cardiovascular disease, heart failure and sleep apnea. A separate trial is testing injections every eight weeks or quarterly in patients switching from weekly Tirzepatide or Semaglutide. Less frequent dosing could give patients another reason to choose the treatment if it wins approval.</p><p>Novo Nordisk (NVO) will report on Wednesday, with sales of the Wegovy pill and higher-dose injection offering a check on demand. Weekly U.S. prescriptions for the pill topped 265,000 by mid-July. Novo raised its outlook in August, though it still expected adjusted sales and operating profit to range from a 6% decline to no growth, excluding currency effects.</p><p>Madrigal Pharmaceuticals (MDGL) also will report on Tuesday, giving investors a look at demand for its liver-disease drug Rezdiffra.</p><h2 class="st-heading-2"><strong>Iovance Balances Melanoma Sales With Lung-Cancer Plans</strong></h2><p>Iovance Biotherapeutics (IOVA) will report on Thursday. Investors will get an update on Amtagvi, a treatment that uses patients’ own immune cells to fight advanced melanoma, as the company works to expand into lung cancer.</p><p>Results released last month showed a 24.6% response rate among 69 previously treated lung-cancer patients. That rose to 59.1% in a 22-patient subgroup identified using tumor genetics and smoking history. Iovance plans to begin enrolling its Positility cohort in November to test that selection strategy prospectively. A filing for Lifileucel in the broader previously treated lung-cancer population is planned for 2027.</p><h2 class="st-heading-2"><strong>Moderna’s Earnings Go Beyond Vaccine Sales</strong></h2><p>Moderna (MRNA) will report on Friday, with investors weighing seasonal vaccine sales alongside progress on its personalized cancer vaccine. The company previously targeted up to 10% revenue growth for 2026 and expected about 55% of its second-half revenue to come in the third quarter.</p><p>Its update could also bring more detail on regulatory plans for Intismeran Autogene. Last month, Moderna and Merck (MRK) said the experimental vaccine, combined with Merck’s immunotherapy Keytruda, reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone in a Phase 3 trial. Overall-survival data are still being collected.</p><h2 class="st-heading-2"><strong>New Cancer Findings Arrive At SITC</strong></h2><p>The Society for Immunotherapy of Cancer’s annual meeting and pre-conference programs run Nov.4-Nov.8 in Phoenix. Regular research abstracts become public on Tuesday, followed by late-breaking findings on Friday.</p><p>Immunocore (IMCR) will present early results for Brenetafusp alone and with Kimmtrak in metastatic uveal melanoma, an eye cancer that has spread. Both drugs help direct immune cells called T cells to attack cancer. Additionally, Candel Therapeutics (CADL) will present lung-cancer findings Friday in patients whose disease progressed despite earlier immunotherapy. On Saturday, it will share early findings in recurrent glioblastoma, an aggressive brain cancer.</p><h2 class="st-heading-2"><strong>Inovio Gets FDA Approval As Agios Faces A Delay</strong></h2><p>Two names from last week’s FDA watchlist head into November with different outcomes: an approval for Inovio Pharmaceuticals (INO) and a longer wait for Agios Pharmaceuticals (AGIO).</p><p>On Friday, the FDA granted accelerated approval to Inovio’s Voceryq, formerly INO-3107, for adults with recurrent respiratory papillomatosis. The rare HPV-related disease causes recurring airway growths that can require repeated surgery.&nbsp;</p><p>Meanwhile, the FDA extended its review of Agios’ Mitapivat for sickle cell disease to Feb.1, 2027, from Nov.1. The agency is considering whether a risk-management program is needed and classified additional safety information as a major amendment, triggering the three-month extension.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p><p>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spcx-stock-musk-tsmc-terafab-talks-capex-efficiency-greatly-underestimated/cNG9KfcR92f">SPCX Stock Jumps Overnight: Musk Reportedly Revives TSMC Terafab Talks — Says Capex Efficiency Is ‘Greatly Underestimated’&nbsp;</a></p>

Biotech Stocks Beat The S&P500 – Can Pfizer, Novo And Moderna Earnings Keep The Rally Going?

Agios Pharmaceuticals Inc

AMGEN Inc.

BioNTech SE - ADR

Candel Therapeutics Inc

iShares Biotechnology ETF

Immunocore Holdings PLC - ADR

Inovio Pharmaceuticals Inc

Iovance Biotherapeutics Inc

Madrigal Pharmaceuticals Inc

Merck & Co Inc

Moderna Inc

Novo Nordisk A/S

Pfizer Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

VRTX News